ARS Pharmaceuticals (SPRY) Insider Saunders Buys 30,000 Shares
Brent Saunders buys shares of ARS Pharmaceuticals, joining several insiders in recent purchases.
Reviewed by automated data checks against the source filing. How we make and check alerts
Brent Saunders bought 30,000 shares of ARS Pharmaceuticals, Inc. ($SPRY) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SPRY is down 24.7% after 1 week, down 43.6% after 1 month and down 61.9% to date (from the $10.54 close on Jun 24, 2026).
SPRY
ARS Pharmaceuticals, Inc.
Key Points
- Brent Saunders bought 30,000 shares of ARS Pharmaceuticals at $8.54 each on June 24, 2026.
- The stock currently trades at $8.54, above its 52-week low of $4.07 but below its high of $13.15.
- ARS Pharmaceuticals has a strong buy rating from analysts, with a mean price target of $22.5.
Get $SPRY trade alerts by text
We text you when insiders, Congress or big funds trade $SPRY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ARS Pharmaceuticals, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
Brent Saunders bought 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026, at a price of $8.54 per share. This purchase reflects a growing confidence in the company's potential as it prepares for its next earnings report on November 10, 2026. This is part of a series of significant insider purchases on the same day.
A Wave of Insider Buying
On June 24, several insiders also bought shares of ARS Pharmaceuticals. Phillip Schneider, Pratik Shah, Saqib Islam, Laura Shawver, Peter Thompson, and L.P. Ra Capital Management each acquired 30,000 shares, signaling strong internal confidence in the company's future. Each of these transactions occurred at the same time as Saunders' purchase, reinforcing a collective belief in the company's prospects.
Stock Performance Context
The stock is currently trading at $8.54, which is above its 52-week low of $4.07 but significantly below its 52-week high of $13.15. This recent insider activity comes as the stock has been fluctuating within this range, possibly indicating an opportunity for recovery as analysts maintain a strong buy rating with a mean price target of $22.5.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained an outperform rating on ARS Pharmaceuticals, adjusting its price target from $25.0 to $24.0. This followed a prior rating on August 13, where the firm adjusted the target to $18.0. With four analyst opinions, the consensus remains positive, highlighting the company's potential for growth.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for severe allergic reactions. The firm is well-known for its needle-free delivery system for epinephrine, which is crucial for emergency treatments of anaphylaxis. With a market cap of approximately $432.6 million, the company operates in a vital sector of healthcare.
What to Watch at ARS Pharmaceuticals, Inc.
Investors should keep an eye on the upcoming earnings report on November 10, 2026. The recent insider buying suggests that these executives believe in the company's future, and the 13F filings may reflect more changes in positions as they become available. As always, the 13F filings provide a backward-looking view of holdings and may not represent current positions.
Related Filing Alerts
Source: Brent Saunders's Form 4 filing on $SPRY (Jun 24, 2026). Find the original filing: SPRY Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts